



NDA 212539  
NADA 141-507

**DEEMED GRANTED -  
MEDICAL GAS CERTIFICATION REQUEST**

**Matheson Tri-Gas, Inc.**  
Attention: Bonnie J. Strange  
Corp. Director FDA Regulatory Compliance  
1916 2<sup>nd</sup> Street NW  
Albuquerque, NM 87102

Dear Ms. Strange:

Please refer to your August 10, 2018, request, received on August 17, 2018, for certification of Helium, USP, as a designated medical gas. You have requested to market Helium, USP, for both human and animal use.

A request for certification of a medical gas as a designated medical gas submitted under section 575(a)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) is deemed to be granted unless, within 60 days of the filing of the request, FDA finds that one or more of the bases for denying the request listed at section 575(a)(2) of the FD&C Act applies. FDA has made no such finding in connection with your request, and 60 days have passed since your request was filed. Accordingly, by operation of section 575(a)(2) of the FD&C Act, your request for certification of Helium, USP as a designated medical gas is deemed to be granted, and you now have in effect an approved new drug application (NDA 212539) for human drug use and an approved new animal drug application (NADA 141-507) for animal drug use for this gas effective 10/16/2018.

We remind you that if you make any changes to the information in your certification request, such as where the gas is manufactured, how it is manufactured, or changes in applicant information, you will need to submit an updated certifications request to these same application numbers. Send all correspondences concerning this application to the following address:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Pharmaceutical Quality  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

Please include the NDA and NADA numbers listed above at the top of the first page of any such communications.

NDA 212539  
NADA 141-507  
Page 2

If you have any questions, please contact Michael Folkendt at (301) 796-1670 or by email at michael.folkendt@fda.hhs.gov.

Sincerely,



Digitally signed by  
Charles J. Andres -S  
Date: 2018.12.20  
07:43:24 -05'00'

Charles J. Andres, Ph.D.  
Director  
Division of Business Information Science and Management  
Office of New Animal Drug Evaluation, HFV-180  
Center for Veterinary Medicine  
FDA

Michael M.  
Folkendt -S

Digitally signed by Michael M. Folkendt -S  
DN: c=US, o=U.S. Government, ou=HHS,  
ou=FDA, ou=People,  
0.9.2342.19200300.100.1.1=1300085536,  
cn=Michael M. Folkendt -S  
Date: 2018.12.20 10:25:19 -05'00'

Michael Folkendt  
Deputy Director (Acting)  
Office of Program and Regulatory Operations  
Office of Pharmaceutical Quality  
CDER/FDA